-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

Benzinga·08/31/2026 17:34:13
Listen to the news
Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.